Stock symbol SETI not yet supported on Stock Buzz.
|
SocialPicks Sentiment:
N/A
** not enough data to be rated
|
This Quarter's Sentiment:
|
|
|
PCYC Analysis & Videos »
PCYC: Bull or Bear?
Pharmacyclics Inc.
PCYC
|
|
|
+4.44%
in
502 days
Pharmacyclics, Inc., a pharmaceutical company, is developing drugs to treat cancer and other diseases. Its pharmaceutical agents are synthetic small molecules designed to target key biochemical pathways in diseased cells. The company’s product candidate, Xcytrin (motexafin gadolinium) Injection, an anti-cancer agent with a novel mechanism of action, has completed Phase III trials in oncology and is in Phase II trials for patients with non-small cell lung cancer. Its products also include PCI-24781, a histone deacetylase inhibitor in Phase I trial in patients with advanced relapsed < /><><><><><><>< /><><><><><><><><>...
|
FDA files NDA for Pharmacyclics drug Xcytrin
PCYC
|
|
|
+1.52%
in
3 days
(closed on 04/26/07)
Today, the FDA filed the NDA for Xcytrin. In most cases this would be great news. However, they chose to review the drug over the next 8 months and have until Dec 31st t to make their final decision to approve or not. Given that Xcytrin was designated a fast track and Orphan drug it was surprising they chose the longer time frame for review.
Long term the news is still good for Pharmacyclics but this extended delay will likely cause the stock price to drop back into the high $2 to low $3 range.
|
Pharmacyclics Challenges FDA
PCYC
|
|
|
+19.27%
in
19 days
(closed on 04/23/07)
Pharmacyclics is a small start-up pharmaceutical company that has developed a novel cancer treatment for small-cell lung cancer. Their drug Xcytrin received Orphan drug status and was placed on the fast track due to the promising results of initial trials and the uniqueness of the drug. They recently completed phase III trials with an international study. The study results initially did not show significant results. When exploring further it was determined that the non-US portion of the population received initial treatment significantly later in the process following diagnosis than the< />< /><>...
|
Bullish on PCYC ...
PCYC
|
|
|
-32.51%
in
193 days
(closed on 04/14/07)
15% held by owners, HUGE amount of insider buying recently by benificial owner, clean balence sheet almost no debt, recent breakout above trading channel and above 200 moving day average, recent upgrade by BWS Financial, low targer 5.50
|
People Bullish on PCYC
People Bearish on PCYC
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on PCYC |
Be the first to start a discussion and earn 2 points.
More Resources
|
About Pharmacyclics Inc.
- Answers.com
